Article

Top 5 Pharmacy Times Articles in 2022

From newsworthy moments to groundbreaking research, these were the most-read articles on Pharmacy Times in 2022.

1. Let’s Not Sugar Coat It: HbA1c is the Imperfect Diabetes Diagnostic

When diabetes is uncontrolled, higher percentages of hemoglobin become glycated, which causes elevated HbA1c and glucose levels to rise within the body. Read more.

2. New Binding Mechanism Science Driving Therapeutic Insight in Immune-Mediated Diseases

The ability of an anti-interleukin-23 antibody to bind to key immune system components may help neutralize a key driver of inflammation right at its cellular source. Read more.

3. Pharmacist Medication Insights: Signs of Taking Too Much Vitamin D

Without sufficient vitamin D exposure, bones can become thin, brittle, or misshapen; however, excessive amounts of vitamin D are toxic. Read more.

4. Booster Dose of AstraZeneca COVID-19 Vaccine Significantly Increases Levels of Antibodies Against Omicron Variant

The study analyzed blood samples taken from individuals infected with COVID-19, those who had been vaccinated with a 2-dose schedule and a third booster dose, and those who had reported previous infection from other COVID-19 variants of concern. Read more.

5. Higher Incidence of Myocarditis, Pericarditis Found After COVID-19 Vaccination

Despite evidence of a higher risk of myocarditis or pericarditis with COVID-19 vaccination, immunization should still be recommended because the benefits likely outweigh the harms, study shows. Read more.

Related Videos
Heart with stethoscope | Image Credit: © DARIKA - stock.adobe.com
Senior Doctor is examining An Asian patient.
Healthcare, pharmacist and woman at counter with medicine or prescription drugs sales at drug store.
Image Credit: © Birdland - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix